The results showed that abnormal p53 expression, manifested as either overexpression or lack of expression, was correlated with poorer patient prognosis and resistance to androgen deprivation therapy, which is commonly used in prostate cancer treatment. This evidence concerns the gene TP53 and Familial prostate cancer.